Nitinol Device (TIND -MediTateâ) is a new device for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). We already published the feasibility and safety of TIND implantation, herein we report the results of a one-arm, multi-center, international prospective study to assess the efficacy of second generation of MediTate i-TIND in subjects with BPH.
INTRODUCTION AND OBJECTIVES: Temporary Implantable
Nitinol Device (TIND -MediTateâ) is a new device for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). We already published the feasibility and safety of TIND implantation, herein we report the results of a one-arm, multi-center, international prospective study to assess the efficacy of second generation of MediTate i-TIND in subjects with BPH.
METHODS: The i-TIND is comprised of three nitinol elongated struts and an anchoring leaflet and it is preloaded by crimping it into the delivery system. In expanded configuration, the struts of the i-TIND exert radial force that causes ischemic necrosis and subsequent incisions of bladder neck and prostatic urethra. i-TIND was implanted under light sedation, using a rigid 22F cystoscope. The device was removed 5 days later in an outpatient setting, with no need of anesthesia. Forty patients with LUTS were enrolled in this multi-center study from Oct 2014. Inclusion criteria were: IPSS score ¼ 10, peak urinary flow (Qmax) < 12 ml/sec and prostate volume < 75 cc. All patients discontinued medical therapy for BPH before the implantation.
Demographics, perioperative, functional results and quality of life (QoL) were evaluated. For the purpose of this study we reported the results of 3 and 6 months follow-up.
RESULTS: Patients' age (mean+ SD) was 65.7 y (9.1) and BMI (mean+ SD) was 26.5 (4.1). Prostate volume (mean+ SD), IPSS score (median, range), QoL (median, range) and Qmax (mean+ SD), were 35.3 (+12.5) cc, 25(13-35), 4 (2-5), and 7.5 (2.87) ml/sec respectively. All the implantations and the removals of device were successfully concluded with no intraoperative complications. Three months after implantation IPSS score, QoL and Qmax were 7 (1-29), 1 (0-5) and 12.4ml/sec (4.9); after six months were 7 (0-29), 2 (0-4) and 14 ml/sec (+6.01) respectively. No patients reported ejaculatory dysfunction during follow-up. Differences in terms of IPSS score, QoL and Qmax when comparing preoperative and 6 months postoperative results were statistically significant (p<0.05); specifically the mean change from baseline to month 6 in IPSS score was -15.33 and the mean change of Qmax was 6.2 ml/sec. During the follow up no patients required pharmacologic treatment or surgery for BPH.
CONCLUSIONS: Second generation i-TIND implantation is a safe and effective minimally-invasive option for the treatment of BPH related LUTS at least at short term follow up. Further studies are required to assess durability of these results. METHODS: From December 2013 to January 2016, 123 patients with LUTS due to BPO underwent endoscopic enucleation of the prostate (67 GreenLEP and 56 HoLEP) in two centers by two surgeons with no previous enucleation experience. Perioperative data (prostate volume, operative times, Clavien-Dindo complications and functional outcomes (IPSS score, Qmax)) were prospectively collected. Statistical analysis retrospectively compared the two surgical techniques. To assess the impact of the learning curve, patients were divided in two groups: group1, the first half of experience and group2, the second half, in each technique (Chi2 test and ANOVA).
RESULTS: Mean prostate volumes were 124.2 and 72.3 g in GreenLEP and HoLEP groups, respectively (p<0.001). Mean enucleation and morcellation times were shorter in GreenLEP group (63.5 vs 80.4 min and 0.15 vs 0.24 min/g, p<0.001 and p¼0.005, respectively) ( Table 1) . Operative times were lower in GreenLEP group (0.87 vs 1.6min/g, p<0.001). Ten patients experienced TURP conversion for hemostasis in GreenLEP group (90% in the sub group1), no in HoLEP group (p¼0.003). Hospital stay was longer in HoLEP group (4.2 vs 2.5 days, p>0.001). Operative parameters (operative time and hospital stay) were improved in the group1 (p<0.001). Mean IPSS scores were lower in GreenLEP group while post-operative PSA levels were similar (Fig 1) .
CONCLUSIONS: In the learning curve, GreenLEP provides promising results and comparable functional outcomes to HoLEP technique with a possible shorter operative time and hospital stay. (HoLEP) is an established effective alternative treatment option to the traditional transurethral resection of the prostate for bladder outflow obstruction secondary to benign prostatic hyperplasia. As a relatively new procedure long-term outcomes for patients undergoing HoLEP are still being studied. We describe the complications of a large single centre case series with up to 13 years of postoperative follow-up.
METHODS: A retrospective review of a prospective database of all HoLEP procedures performed by or under supervision of a single consultant urological surgeon was undertaken. All case notes were e512 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
